Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-World Danish Observational Cohort Study to Evauate Effectiveness and Safety of Edoxaban in Patients with Atrial Fibrillation

Trial Profile

A Real-World Danish Observational Cohort Study to Evauate Effectiveness and Safety of Edoxaban in Patients with Atrial Fibrillation

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Stroke; Thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Dec 2019 New trial record
    • 18 Dec 2019 According to a Daiichi Sankyo Europe GmbH media release, Assoc. Professor Peter Bronnum Nielsen (Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Denmark) is the lead author of this study.
    • 18 Dec 2019 According to a Daiichi Sankyo Europe GmbH media release, results of this Danish observational cohort study were published in the European Heart Journal-Cardiovascular Pharmacotherapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top